Ipamorelin vs CJC-1295: Which One (or Both)?

Ipamorelin and CJC-1295 get compared like rivals, but they are not really the same kind of compound. They act on two separate growth hormone pathways, which is exactly why so many research protocols describe them together instead of as an either/or choice.

This page breaks down what each one is, why the pair shows up so often, and the tradeoffs of running either on its own. All framing here is educational. These are research compounds not approved for human use, and any protocol decision belongs with a licensed clinician.

Two different jobs: GHRP vs GHRH

The core difference is mechanism. Ipamorelin is a growth hormone releasing peptide (GHRP), also called a ghrelin mimetic. It signals a pulse of growth hormone and is known for being selective, meaning it does not meaningfully spike cortisol or prolactin the way older GHRPs were noted to.

CJC-1295 is a growth hormone releasing hormone (GHRH) analog. Instead of triggering a pulse on its own, it raises the baseline signal and amplifies the size of the pulse the body produces. Think of one as pressing the button and the other as turning up the volume.

• Ipamorelin (GHRP): initiates a release pulse, selective profile.
• CJC-1295 (GHRH): increases the amplitude and baseline of that pulse.
• Together: the two signals stack, which is the reason they are combined.

Why they get combined

A GHRP and a GHRH act on different receptors, so their effects are additive rather than redundant. In the research literature, pairing a releasing peptide with a releasing hormone is described as producing a larger combined signal than either input alone. That synergy is the whole reason the stack exists, and it is why a single product often contains both.

There is also a half-life angle. Plain CJC-1295 without DAC is short acting and clears quickly, which lines up well with the short pulse from ipamorelin. The DAC version (Drug Affinity Complex) extends the half-life to several days, which changes the dosing rhythm completely. For more on that split, see CJC-1295 with vs without DAC.

Solo-use tradeoffs

Each can be referenced on its own, but the tradeoffs differ.

• Ipamorelin alone: a clean, selective pulse, but you lose the amplitude boost that GHRH adds.
• CJC-1295 alone: raises baseline signal, but without a GHRP there is no triggered pulse to amplify.
• The two solo, side by side: this is why most reference charts describe the combined approach rather than choosing one.

If you are weighing ipamorelin against a different GHRH like sermorelin, the comparison in ipamorelin vs sermorelin covers that angle directly.

The reconstitution math

Because a blend often arrives as two compounds in one vial, the dosing math matters. Say a vial holds 5 mg of CJC-1295 and 5 mg of ipamorelin, and you add 2 mL of bacteriostatic water. That gives 5 mg per mL for each compound, or 2.5 mg per mL each across the full 2 mL fill. On a U-100 insulin syringe, 1 mL equals 100 units, so 0.1 mL (10 units) would carry roughly 250 mcg of each compound.

Rather than run that by hand, the CJC-1295 + ipamorelin calculator handles the per-compound concentration and the unit mark on the syringe for you. For the general method, the reconstitution calculator and our mg to units guide cover the same conversion for any peptide.

Quick reference

• Different mechanisms: GHRP (ipamorelin) vs GHRH (CJC-1295).
• Combined because the two signals are additive, not redundant.
• CJC-1295 comes in short-acting (no DAC) and long-acting (DAC) forms.
• Solo use loses the synergy that makes the pair common.
• Dose a blend per compound, not by total volume.

For dosing-schedule reference numbers, the CJC-1295 + ipamorelin dosage guide lays out common research figures. Track each reconstitution and draw in the Stackr app so your concentration and unit math stay consistent. None of this is medical advice; see the disclaimer.